ASX:RCE - Recce Pharmaceuticals Stock Price, News, & Analysis

0.00 (0.00 %)
(As of 06/16/2019 04:00 PM ET)
Today's Range
Now: A$0.21
50-Day Range
MA: A$0.22
52-Week Range
Now: A$0.21
Volume159,867 shs
Average VolumeN/A
Market Capitalization$21.96 million
P/E RatioN/A
Dividend YieldN/A
Recce Pharmaceuticals Ltd, a biotechnology company, researches and develops antibiotic drugs in Australia. The company focuses on the development of RECCE 327 that helps to address the problem of antibiotic resistant superbugs. It also develops drugs for the treatment of stomach ulcers and diarrhea. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.

Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Phone61 2 8075 4585



Sales & Book Value

Annual Sales$1.54 million
Cash FlowA$0.01 per share
Book ValueA$0.00 per share



Market Cap$21.96 million
Next Earnings DateN/A
OptionableNot Optionable

Receive RCE News and Ratings via Email

Sign-up to receive the latest news and ratings for RCE and its competitors with MarketBeat's FREE daily newsletter.

Recce Pharmaceuticals (ASX:RCE) Frequently Asked Questions

What is Recce Pharmaceuticals' stock symbol?

Recce Pharmaceuticals trades on the ASX under the ticker symbol "RCE."

Has Recce Pharmaceuticals been receiving favorable news coverage?

Media stories about RCE stock have trended somewhat positive on Sunday, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Recce Pharmaceuticals earned a news impact score of 1.2 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Recce Pharmaceuticals.

Who are some of Recce Pharmaceuticals' key competitors?

What other stocks do shareholders of Recce Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Recce Pharmaceuticals investors own include FlexiGroup (FXL), ASE Technology (ASX), IMMUTEP LTD/S (IMMP), Mavenir Systems (MVNR), Organovo (ONVO), Micron Technology (MU), Seres Therapeutics (MCRB), First Graphene (FGR), Turtle Beach (HEAR) and Cree (CREE).

Who are Recce Pharmaceuticals' key executives?

Recce Pharmaceuticals' management team includes the folowing people:
  • Dr. Graham John Hamilton Melrose BSc(Hons), Ph.D., MBA, FRACI, CChem, FAICD, Exec. Chairman & Chief Research Officer (Age 85)
  • Mr. James Hamilton-Bray Graham, Exec. Director and Exec. Director of Marketing & Bus. Devel.
  • Ms. Michele Dilizia, Exec. Director and Exec. Director of Regulatory Affairs & Microbiology
  • Dr. Justin Ward, Principal Quality Chemist
  • Mr. Justin Reynolds, Chief Financial Officer

What is Recce Pharmaceuticals' stock price today?

One share of RCE stock can currently be purchased for approximately A$0.21.

How big of a company is Recce Pharmaceuticals?

Recce Pharmaceuticals has a market capitalization of $21.96 million and generates $1.54 million in revenue each year. View Additional Information About Recce Pharmaceuticals.

What is Recce Pharmaceuticals' official website?

The official website for Recce Pharmaceuticals is

How can I contact Recce Pharmaceuticals?

The company can be reached via phone at 61 2 8075 4585.

MarketBeat Community Rating for Recce Pharmaceuticals (ASX RCE)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  5 (Vote Outperform)
Underperform Votes:  3 (Vote Underperform)
Total Votes:  8
MarketBeat's community ratings are surveys of what our community members think about Recce Pharmaceuticals and other stocks. Vote "Outperform" if you believe RCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RCE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/16/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel